skip to content
Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention : clinical and cost-effectiveness analyses Preview this item
ClosePreview this item
Checking...

Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention : clinical and cost-effectiveness analyses

Author: Stella Chen; Canadian Agency for Drugs and Technologies in Health.
Publisher: Ottawa, Ont. : Canadian Agency for Drugs and Technologies in Health, 2010.
Series: Technology report (Canadian Agency for Drugs and Technologies in Health), 131.
Edition/Format:   eBook : Document : EnglishView all editions and formats
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Electronic books
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Stella Chen; Canadian Agency for Drugs and Technologies in Health.
OCLC Number: 758077194
Notes: "November 2010."
Description: 1 online resource (xi, 91, A86 pages) : illustrations, digital file.
Contents: 6. Health services impact. 6.1. Population impact --
6.2. Budget impact: 6.2.1. Methods; 6.2.2. Results; 6.2.3. Budget impact analysis; 6.2.4. Sensitivity analyses --
6.3. Planning, implementation, utilization, and legal or regulatory considerations --
6.4. Ethical considerations: 6.4.1. Efficiency versus equity --
6.5. Psychosocial considerations. 7. Discussion: 7.1. Summary of results; 7.2. Strengths and weaknesses of this assessment; 7.3. Generalizability of findings; 7.4. Knowledge gaps --
8. Conclusions --
9. References. Appendix 1: Restricted, limited, exceptional medication --
Appendix 2: Drug plans covered --
Appendix 3: Literature search strategy --
Appendix 4: Data extraction form for clinical review --
Appendix 5: Quality assessment form --
Appendix 6: Excluded clinical studies --
Appendix 7: Trial characteristics (RCT) --
Appendix 8: Inclusion and exclusion criteria for study participants --
Appendix 9: Patient characteristics of included studies (RCT) --
Appendix 10: Quality assessment of studies --
Appendix 11: Definitions of outcomes as provided by the investigators --
Appendix 12: MTC network diagrams --
Appendix 13: Raw data for MTC analyses --
Appendix 14: MTC model code: Winbugs --
Appendix 15: Adverse events --
Appendix 16: Guidelines for secondary prevention of cardiovascular and cerebrovascular events in PCI patients --
Appendix 17: Appraisal of guidelines research and evaluation (AGREE) standardized domain scores --
Appendix 18: Economic data extraction sheet --
Appendix 19: Full text economic articles obtained for review as potentially relevant --
Appendix 20: Quality of reporting in the economic evaluations included in the review --
Appendix 21: Antiplatelet prescription and expenditures by jurisdictions, all indications. 5. Economic analysis. 5.1. Review of economic studies: methods: 5.1.1. Literature searches; 5.1.2. Selection criteria; 5.1.3. Selection method; 5.1.4. Data extraction strategy; 5.1.5. Strategy for validity assessment; 5.1.6. Data analysis methods --
5.2. Review of economic studies: results: 5.2.1. Perspectives; 5.2.2. Intervention and comparators; 5.2.3. Baseline disease; 5.2.4. Treatment effectiveness; 5.2.5. Costs; 5.2.6. Utilities; 5.2.7. Modelling frameworks; 5.2.8. Analysis methods; 5.2.9. Validity; 5.2.10. Results and conclusions --
5.3. Primary economic evaluation: methods: 5.3.1. Type of economic evaluation; 5.3.2. Target population; 5.3.3. Comparator and interventions; 5.3.4. Perspective; 5.3.5. Time horizon; 5.3.6. Modelling; 5.3.7. Costs; 5.3.8. Valuing outcomes; 5.3.9. Discount; 5.3.10. Variability and uncertainty; 5.3.11. Equity --
5.4. Primary economic evaluation: results: 5.4.1. Analysis and results; 5.4.2. Results of variability analysis; 5.4.3. Results of uncertainty analysis; 5.4.4. Results of probabilistic analysis; 5.4.5. Results of value of information analysis. 1. Introduction: 1.1. Background and setting in Canada; 1.2. Overview of technology --
2. The issue --
3. Objectives. 4. Clinical review. 4.1. Methods: 4.1.1. Literature search strategy; 4.1.2. Selection criteria; 4.1.3. Selection method; 4.1.4. Data extraction strategy; 4.1.5. Strategy for validity assessment; 4.1.6. Data analysis methods --
4.2. Results: 4.2.1. Quantity of research available; 4.2.2. Study characteristics; 4.2.3. Data analyses and synthesis; 4.2.4. Guidelines review.
Series Title: Technology report (Canadian Agency for Drugs and Technologies in Health), 131.
Responsibility: Stella Yue Chen [and others].
More information:

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


\n\n

Primary Entity<\/h3>\n
<http:\/\/www.worldcat.org\/oclc\/758077194<\/a>> # Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention : clinical and cost-effectiveness analyses<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:CreativeWork<\/a>, schema:Book<\/a>, schema:MediaObject<\/a> ;\u00A0\u00A0\u00A0\nlibrary:oclcnum<\/a> \"758077194<\/span>\" ;\u00A0\u00A0\u00A0\nlibrary:placeOfPublication<\/a> <http:\/\/id.loc.gov\/vocabulary\/countries\/onc<\/a>> ;\u00A0\u00A0\u00A0\nlibrary:placeOfPublication<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Place\/ottawa_ont<\/a>> ; # Ottawa, Ont.<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/ticlopidine_analogs_&_derivatives<\/a>> ; # Ticlopidine--analogs & derivatives<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/hematologic_agents_therapeutic_use_cost_effectiveness<\/a>> ; # Hematologic agents--Therapeutic use--Cost effectiveness<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/clopidogrel_therapeutic_use_cost_effectiveness<\/a>> ; # Clopidogrel--Therapeutic use--Cost effectiveness<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/id.loc.gov\/authorities\/subjects\/sh85015003<\/a>> ; # Blood platelets--Aggregation<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/drug_eluting_stent<\/a>> ; # Drug-eluting stent<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/coronary_artery_disease<\/a>> ; # Coronary artery disease<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/cardiovascular_disease<\/a>> ; # Cardiovascular disease<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/coronary_stent<\/a>> ; # Coronary stent<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/peripheral_vascular_diseases_chemotherapy<\/a>> ; # Peripheral vascular diseases--Chemotherapy<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/coronary_heart_disease_chemotherapy<\/a>> ; # Coronary heart disease--Chemotherapy<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/clopidogrel<\/a>> ; # Clopidogrel<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/clopidogrel_therapeutic_use<\/a>> ; # Clopidogrel--Therapeutic use<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/blood_platelets_aggregation<\/a>> ; # Blood platelets--Aggregation<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/atheroma<\/a>> ; # Atheroma<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/clinical_medicine<\/a>> ; # Clinical medicine<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/dewey.info\/class\/615.718\/e22\/<\/a>> ;\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/platelet_aggregation_inhibitors_therapeutic_use<\/a>> ; # Platelet Aggregation Inhibitors--therapeutic use<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/acute_coronary_syndrome_drug_therapy<\/a>> ; # Acute Coronary Syndrome--drug therapy<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/clinical_trial<\/a>> ; # Clinical trial<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/atherosclerosis<\/a>> ; # Atherosclerosis<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/cost_benefit_analysis<\/a>> ; # Cost-Benefit Analysis<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/antiplatelet_drug<\/a>> ; # Antiplatelet drug<\/span>\n\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/hematologic_agents_cost_effectiveness<\/a>> ; # Hematologic agents--Cost effectiveness<\/span>\n\u00A0\u00A0\u00A0\nschema:bookFormat<\/a> schema:EBook<\/a> ;\u00A0\u00A0\u00A0\nschema:contributor<\/a> <http:\/\/viaf.org\/viaf\/145374402<\/a>> ; # Canadian Agency for Drugs and Technologies in Health.<\/span>\n\u00A0\u00A0\u00A0\nschema:contributor<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Person\/chen_stella<\/a>> ; # Stella Chen<\/span>\n\u00A0\u00A0\u00A0\nschema:copyrightYear<\/a> \"2010<\/span>\" ;\u00A0\u00A0\u00A0\nschema:datePublished<\/a> \"2010<\/span>\" ;\u00A0\u00A0\u00A0\nschema:datePublished<\/a> \"2011<\/span>\" ;\u00A0\u00A0\u00A0\nschema:description<\/a> \"1. Introduction: 1.1. Background and setting in Canada; 1.2. Overview of technology -- 2. The issue -- 3. Objectives.<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\nschema:description<\/a> \"Appendix 1: Restricted, limited, exceptional medication -- Appendix 2: Drug plans covered -- Appendix 3: Literature search strategy -- Appendix 4: Data extraction form for clinical review -- Appendix 5: Quality assessment form -- Appendix 6: Excluded clinical studies -- Appendix 7: Trial characteristics (RCT) -- Appendix 8: Inclusion and exclusion criteria for study participants -- Appendix 9: Patient characteristics of included studies (RCT) -- Appendix 10: Quality assessment of studies -- Appendix 11: Definitions of outcomes as provided by the investigators -- Appendix 12: MTC network diagrams -- Appendix 13: Raw data for MTC analyses -- Appendix 14: MTC model code: Winbugs -- Appendix 15: Adverse events -- Appendix 16: Guidelines for secondary prevention of cardiovascular and cerebrovascular events in PCI patients -- Appendix 17: Appraisal of guidelines research and evaluation (AGREE) standardized domain scores -- Appendix 18: Economic data extraction sheet -- Appendix 19: Full text economic articles obtained for review as potentially relevant -- Appendix 20: Quality of reporting in the economic evaluations included in the review -- Appendix 21: Antiplatelet prescription and expenditures by jurisdictions, all indications.<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\nschema:description<\/a> \"5. Economic analysis. 5.1. Review of economic studies: methods: 5.1.1. Literature searches; 5.1.2. Selection criteria; 5.1.3. Selection method; 5.1.4. Data extraction strategy; 5.1.5. Strategy for validity assessment; 5.1.6. Data analysis methods -- 5.2. Review of economic studies: results: 5.2.1. Perspectives; 5.2.2. Intervention and comparators; 5.2.3. Baseline disease; 5.2.4. Treatment effectiveness; 5.2.5. Costs; 5.2.6. Utilities; 5.2.7. Modelling frameworks; 5.2.8. Analysis methods; 5.2.9. Validity; 5.2.10. Results and conclusions -- 5.3. Primary economic evaluation: methods: 5.3.1. Type of economic evaluation; 5.3.2. Target population; 5.3.3. Comparator and interventions; 5.3.4. Perspective; 5.3.5. Time horizon; 5.3.6. Modelling; 5.3.7. Costs; 5.3.8. Valuing outcomes; 5.3.9. Discount; 5.3.10. Variability and uncertainty; 5.3.11. Equity -- 5.4. Primary economic evaluation: results: 5.4.1. Analysis and results; 5.4.2. Results of variability analysis; 5.4.3. Results of uncertainty analysis; 5.4.4. Results of probabilistic analysis; 5.4.5. Results of value of information analysis.<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\nschema:description<\/a> \"6. Health services impact. 6.1. Population impact -- 6.2. Budget impact: 6.2.1. Methods; 6.2.2. Results; 6.2.3. Budget impact analysis; 6.2.4. Sensitivity analyses -- 6.3. Planning, implementation, utilization, and legal or regulatory considerations -- 6.4. Ethical considerations: 6.4.1. Efficiency versus equity -- 6.5. Psychosocial considerations.<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\nschema:description<\/a> \"4. Clinical review. 4.1. Methods: 4.1.1. Literature search strategy; 4.1.2. Selection criteria; 4.1.3. Selection method; 4.1.4. Data extraction strategy; 4.1.5. Strategy for validity assessment; 4.1.6. Data analysis methods -- 4.2. Results: 4.2.1. Quantity of research available; 4.2.2. Study characteristics; 4.2.3. Data analyses and synthesis; 4.2.4. Guidelines review.<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\nschema:description<\/a> \"7. Discussion: 7.1. Summary of results; 7.2. Strengths and weaknesses of this assessment; 7.3. Generalizability of findings; 7.4. Knowledge gaps -- 8. Conclusions -- 9. References.<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\nschema:exampleOfWork<\/a> <http:\/\/worldcat.org\/entity\/work\/id\/1029847204<\/a>> ;\u00A0\u00A0\u00A0\nschema:genre<\/a> \"Electronic books<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\nschema:inLanguage<\/a> \"en<\/span>\" ;\u00A0\u00A0\u00A0\nschema:isPartOf<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Series\/cadth_technology_report<\/a>> ; # CADTH technology report ;<\/span>\n\u00A0\u00A0\u00A0\nschema:isPartOf<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Series\/technology_report_canadian_agency_for_drugs_and_technologies_in_health<\/a>> ; # Technology report (Canadian Agency for Drugs and Technologies in Health) ;<\/span>\n\u00A0\u00A0\u00A0\nschema:name<\/a> \"Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention : clinical and cost-effectiveness analyses<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\nschema:productID<\/a> \"758077194<\/span>\" ;\u00A0\u00A0\u00A0\nschema:publication<\/a> <http:\/\/www.worldcat.org\/title\/-\/oclc\/758077194#PublicationEvent\/ottawa_ont_canadian_agency_for_drugs_and_technologies_in_health_2010<\/a>> ;\u00A0\u00A0\u00A0\nschema:publisher<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Agent\/canadian_agency_for_drugs_and_technologies_in_health<\/a>> ; # Canadian Agency for Drugs and Technologies in Health<\/span>\n\u00A0\u00A0\u00A0\nschema:url<\/a> <http:\/\/site.ebrary.com\/id\/10443723<\/a>> ;\u00A0\u00A0\u00A0\nschema:url<\/a> <https:\/\/www.deslibris.ca\/ID\/226554<\/a>> ;\u00A0\u00A0\u00A0\nschema:url<\/a> <http:\/\/epe.lac-bac.gc.ca\/100\/200\/300\/cadth\/2011\/131\/index.html<\/a>> ;\u00A0\u00A0\u00A0\nschema:url<\/a> <http:\/\/books.scholarsportal.info\/viewdoc.html?id=\/ebooks\/ebooks1\/gibson_chrc\/2011-03-23\/1\/10443723<\/a>> ;\u00A0\u00A0\u00A0\nwdrs:describedby<\/a> <http:\/\/www.worldcat.org\/title\/-\/oclc\/758077194<\/a>> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n\n

Related Entities<\/h3>\n
<http:\/\/dewey.info\/class\/615.718\/e22\/<\/a>>\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Agent\/canadian_agency_for_drugs_and_technologies_in_health<\/a>> # Canadian Agency for Drugs and Technologies in Health<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nbgn:Agent<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Canadian Agency for Drugs and Technologies in Health<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Person\/chen_stella<\/a>> # Stella Chen<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Person<\/a> ;\u00A0\u00A0\u00A0\nschema:familyName<\/a> \"Chen<\/span>\" ;\u00A0\u00A0\u00A0\nschema:givenName<\/a> \"Stella<\/span>\" ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Stella Chen<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Place\/ottawa_ont<\/a>> # Ottawa, Ont.<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Place<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Ottawa, Ont.<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Series\/cadth_technology_report<\/a>> # CADTH technology report ;<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nbgn:PublicationSeries<\/a> ;\u00A0\u00A0\u00A0\nschema:hasPart<\/a> <http:\/\/www.worldcat.org\/oclc\/758077194<\/a>> ; # Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention : clinical and cost-effectiveness analyses<\/span>\n\u00A0\u00A0\u00A0\nschema:name<\/a> \"CADTH technology report ;<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Series\/technology_report_canadian_agency_for_drugs_and_technologies_in_health<\/a>> # Technology report (Canadian Agency for Drugs and Technologies in Health) ;<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nbgn:PublicationSeries<\/a> ;\u00A0\u00A0\u00A0\nschema:hasPart<\/a> <http:\/\/www.worldcat.org\/oclc\/758077194<\/a>> ; # Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention : clinical and cost-effectiveness analyses<\/span>\n\u00A0\u00A0\u00A0\nschema:name<\/a> \"Technology report (Canadian Agency for Drugs and Technologies in Health) ;<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/acute_coronary_syndrome_drug_therapy<\/a>> # Acute Coronary Syndrome--drug therapy<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Acute Coronary Syndrome--drug therapy<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/antiplatelet_drug<\/a>> # Antiplatelet drug<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Antiplatelet drug<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/atheroma<\/a>> # Atheroma<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Atheroma<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/atherosclerosis<\/a>> # Atherosclerosis<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Atherosclerosis<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/blood_platelets_aggregation<\/a>> # Blood platelets--Aggregation<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Blood platelets--Aggregation<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/cardiovascular_disease<\/a>> # Cardiovascular disease<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Cardiovascular disease<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/clinical_medicine<\/a>> # Clinical medicine<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Clinical medicine<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/clinical_trial<\/a>> # Clinical trial<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Clinical trial<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/clopidogrel<\/a>> # Clopidogrel<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Clopidogrel<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/clopidogrel_therapeutic_use<\/a>> # Clopidogrel--Therapeutic use<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:hasPart<\/a> <http:\/\/id.loc.gov\/authorities\/subjects\/sh2009007795<\/a>> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Clopidogrel--Therapeutic use<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/clopidogrel_therapeutic_use_cost_effectiveness<\/a>> # Clopidogrel--Therapeutic use--Cost effectiveness<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:hasPart<\/a> <http:\/\/id.loc.gov\/authorities\/subjects\/sh2009007795<\/a>> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Clopidogrel--Therapeutic use--Cost effectiveness<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/coronary_artery_disease<\/a>> # Coronary artery disease<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Coronary artery disease<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/coronary_heart_disease_chemotherapy<\/a>> # Coronary heart disease--Chemotherapy<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:hasPart<\/a> <http:\/\/id.loc.gov\/authorities\/subjects\/sh85032870<\/a>> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Coronary heart disease--Chemotherapy<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/coronary_stent<\/a>> # Coronary stent<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Coronary stent<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/cost_benefit_analysis<\/a>> # Cost-Benefit Analysis<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Cost-Benefit Analysis<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/drug_eluting_stent<\/a>> # Drug-eluting stent<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Drug-eluting stent<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/hematologic_agents_cost_effectiveness<\/a>> # Hematologic agents--Cost effectiveness<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:hasPart<\/a> <http:\/\/id.loc.gov\/authorities\/subjects\/sh88004457<\/a>> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Hematologic agents--Cost effectiveness<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/hematologic_agents_therapeutic_use_cost_effectiveness<\/a>> # Hematologic agents--Therapeutic use--Cost effectiveness<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:hasPart<\/a> <http:\/\/id.loc.gov\/authorities\/subjects\/sh88004457<\/a>> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Hematologic agents--Therapeutic use--Cost effectiveness<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/peripheral_vascular_diseases_chemotherapy<\/a>> # Peripheral vascular diseases--Chemotherapy<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:hasPart<\/a> <http:\/\/id.loc.gov\/authorities\/subjects\/sh85099933<\/a>> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Peripheral vascular diseases--Chemotherapy<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/platelet_aggregation_inhibitors_therapeutic_use<\/a>> # Platelet Aggregation Inhibitors--therapeutic use<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Platelet Aggregation Inhibitors--therapeutic use<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Topic\/ticlopidine_analogs_&_derivatives<\/a>> # Ticlopidine--analogs & derivatives<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Ticlopidine--analogs & derivatives<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/id.loc.gov\/authorities\/subjects\/sh85015003<\/a>> # Blood platelets--Aggregation<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Intangible<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Blood platelets--Aggregation<\/span>\"@en<\/a> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/id.loc.gov\/vocabulary\/countries\/onc<\/a>>\u00A0\u00A0\u00A0\u00A0a \nschema:Place<\/a> ;\u00A0\u00A0\u00A0\ndcterms:identifier<\/a> \"onc<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/viaf.org\/viaf\/145374402<\/a>> # Canadian Agency for Drugs and Technologies in Health.<\/span>\n\u00A0\u00A0\u00A0\u00A0a \nschema:Organization<\/a> ;\u00A0\u00A0\u00A0\nschema:name<\/a> \"Canadian Agency for Drugs and Technologies in Health.<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/www.worldcat.org\/title\/-\/oclc\/758077194<\/a>>\u00A0\u00A0\u00A0\u00A0a \ngenont:InformationResource<\/a>, genont:ContentTypeGenericResource<\/a> ;\u00A0\u00A0\u00A0\nschema:about<\/a> <http:\/\/www.worldcat.org\/oclc\/758077194<\/a>> ; # Clopidogrel versus other antiplatelet agents for secondary prevention of vascular events in adults undergoing percutaneous coronary intervention : clinical and cost-effectiveness analyses<\/span>\n\u00A0\u00A0\u00A0\nschema:dateModified<\/a> \"2020-03-15<\/span>\" ;\u00A0\u00A0\u00A0\nvoid:inDataset<\/a> <http:\/\/purl.oclc.org\/dataset\/WorldCat<\/a>> ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n
<http:\/\/www.worldcat.org\/title\/-\/oclc\/758077194#PublicationEvent\/ottawa_ont_canadian_agency_for_drugs_and_technologies_in_health_2010<\/a>>\u00A0\u00A0\u00A0\u00A0a \nschema:PublicationEvent<\/a> ;\u00A0\u00A0\u00A0\nschema:location<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Place\/ottawa_ont<\/a>> ; # Ottawa, Ont.<\/span>\n\u00A0\u00A0\u00A0\nschema:organizer<\/a> <http:\/\/experiment.worldcat.org\/entity\/work\/data\/1029847204#Agent\/canadian_agency_for_drugs_and_technologies_in_health<\/a>> ; # Canadian Agency for Drugs and Technologies in Health<\/span>\n\u00A0\u00A0\u00A0\nschema:startDate<\/a> \"2010<\/span>\" ;\u00A0\u00A0\u00A0\u00A0.\n\n\n<\/div>\n\n

Content-negotiable representations<\/p>\n